CD30 diagnostics and testing

Optimal quality assurance control and protocol standardization for CD30 staining will be critical for improving testing accuracy and reproducibility of testing (Table 3). Proper sample handling and antigen retrieval are critical, and the detection method used requires standardization (Table 4). Current lymphoma classification integrates a number of immunophenotypic and genomic biomarkers. The addition of CD30 and other biomarkers, such as Bcl-2, Myc, and p53, may offer a better understanding of lymphoma pathogenesis and disease progression, as well as provide critical support for risk stratification and recommendations for treatment regimens. Incorporation of correlative studies with CD30 expression into clinical trials will not only drive a better understanding of the pathophysiology of CD30- positive diseases and the downstream signaling pathway, but also introduce important therapeutic concepts and targets for cancer patients in the near future.

Duke Scholars

Author Ken H Young Pathology